Introduction
In 1983, Isaacson et al. [1] observed that just as nodal lymphomas tended to mimick normal lymph node components, certain B-cell lymphomas of the gastrointestinal tract exhibited features of mucosa-associated lymphoid tissue (MALT). Lymphomas arising from MALT became a distinct clinico-pathologic entity which was later extended to include similar lymphomas in numerous other sites: respiratory tract [2] [3] [4] [5] , salivary glands [6, 7] , thyroid [8] , thymus [9] , breast [10] , skin [11, 12] , liver [13] , conjunctiva [14, 15] , and lachrymal gland and orbital soft tissue [16, 17] .
Most previously documented sites of MALT lymphoma contain non-native lymphoid tissue: the lymphoma arises from a lymphoid population (with the characteristics of MALT) that has been acquired in the course of a chronic inflammatory process, frequently with an autoimmune component.
In contrast to nodal lymphomas, the low-grade MALT lymphomas are often localized at the time of diagnosis and respond favourably to local treatments such as surgery or regional radiation therapy. Furthermore, in comparison to their nodal equivalents, the clinical behaviour of low-grade MALT lymphomas is highly favourable. The relationship of Helicobacter pylori infection to low-grade MALT gastric lymphoma [18] [19] [20] has suggested treatment based on antibiotics and antacids; there have been several reports [21] [22] [23] of eradication by this approach of H. pylori which led to regression or even complete remission of gastric lymphoma. On the other hand, the best treatment for nongastrointestinal MALT lymphomas has not been established.
Herein we summarize a retrospective analysis of our clinical, therapeutical, and prognostic experience in 24 previously untreated stage IE patients with nongastrointestinal low-grade MALT lymphoma.
Patients and methods
Between January 1990 and October 1995, 24 consecutive untreated patients with extranodal nongastrointestinal peripheral B-cell lymphoma of the marginal zone (MALT, low-grade) were treated at our institute. All of them had stage IE according to the Ann Arbor system [24] .
Histological and cytological diagnosis, made solely on the basis of incisional biopsy, transbronchial lung biopsy/bronchoalveolar lavage (BAL) or surgical excision, was determined on Haematossilin-Eosin and Giemsa-stained preparations, supported by immunohistochemical analysis and formulated according to the REAL classification [25] . Diagnosis was followed by staging procedures including initial haematologic and chemical surveys, physical examination, chest radiograms, computerised tomography of the chest and abdomen, abdominal ultrasonography, gastro-duodenoscopy, ORL examination and bone marrow biopsy.
Patient characteristics (Table 1)
Of the 24 patients with nongastrointestinal low-grade MALT lymphomas, eight were males and 16 females, aged from 28 to 75 years (median 55 years). The median duration of their symptoms before diagnosis was 18 months (range 2-32 months). The lymphomas were localized in the lung (seven patients), in conjunctiva (four patients), lachrymal gland and orbital soft tissue (four patients), salivary glands (three patients), skin (three patients), breast (two patients), and thyroid (one patient). All of the patients were in stage IE at the time of diagnosis, and all were HCV-and HIV-negative.
Clinical features and treatment

Pulmonary lymphoma
All seven patients were referred for further evaluation of pulmonary lesions that had been observed on routine chest X-ray and confirmed by computer tomography scan; the lesions were multifocal and bilateral in six cases and localized and monolateral in one case. The patients presented no signs of bronchial obstruction or enlargement of hilar or mediastinal lymph nodes, nor nonspecific pulmonary symptoms such as cough, dyspnea, haemoptysis, or chest pain.
The therapeutic approach varied, and was closely related to the time of diagnosis: six patients received chemotherapy (N-CVP regimen; novantrone, cyclophosphamide, vincristine, prednisone), and one underwent surgery.
Conjunctival lymphoma
In the four patients with a conjunctival site, the lymphoma caused redness and irritation with small fleshy nodules (two on the left and two on the right side); none of the patients presented bilateral tumours. All four patients underwent complete opthalmic examination, including double eversion of the upper eyelids to examine the upper fornix. None of the patients had evidence of tissue involvement other than the conjunctiva; notably, there was no proptosis or orbital disease. All patients underwent biopsies of the upper-and lower-forniceal conjunctivae of both eyes, performed as an office procedure under topical anaesthesia.
Therapy consisted of the local administration of a-IFN (three MU x three times a week) for four to six weeks.
Lachrymal gland and orbital soft tissue lymphoma
The most frequently observed symptoms were swelling, either alone or in association with exophthalmos, lacrimation, burning or diplopia. The lachrymal gland was involved in one case, while the orbit was affected in the remaining three. In all cases the tumor was unilateral. The initial treatment included radiation therapy (3000-3600 cGy) in three patients, and local ot-IFN for the patient with lacrymal gland involvement.
Salivary gland lymphoma
In all three patients the parotid gland was involved (two monolaterally and one bilaterally), but except for an increase in the size of the salivary gland, their lymphomas produced no symptoms. None of the patients suffered from Sjogren's syndrome or other autoimmune disease. All patients received six courses of the CVP (cyclophosphamide, vincristine, and prednisone) polychemotherapy regimen.
Skin lymphoma
All three patients presented only one non-bulky lesion (left arm, right auricle of the ear and chest); no systemic or local symptoms were associated. The initial treatment included excision plus local radiation therapy for all patients.
Breast lymphoma
Both patients presented clinically with a palpable mass (one in the right breast and one in the left). The anatomic locations were upper outer quadrant and subareolar. One patient received only local therapy consisting of excision plus radiation therapy (3000 cGy). The other received local excision and chemotherapy (CHOP regimen, cyclophosphamide, doxorubicin, vincristine, and prednisone).
Thyroid lymphoma
There was no documented history of Hashimoto's thyroiditis, but thyroid antibodies were found. Rapid growth of the thyroid and dysphagia were the symptoms at diagnosis. The patient received local excision, chemotherapy (CHOP regimen) and local radiotherapy (3000 cGy).
Response criteria
Complete response (CR) was defined as the complete absence for at least six weeks of all clinical evidence of the lymphoma, and a reduction of at least 50% of known disease for at least six weeks was rated as a partial response (PR).
Survival and relapse-free survival curves were calculated according to the method of Kaplan-Meier [26] . The survival curve was measured from diagnosis until death; the relapse-free interval was calculated from the end of induction therapy to the first evidence of disease relapse.
Results
All 24 stage IE patients obtained CR. Twenty-one of these patients are still in remission with a median followup of 32 months (range 12-78 months); two of them are in second CR after relapses of eight and 15 months; the other three patients relapsed after 10,16, and 34 months. All patients are alive with a median survival of 34.5 months (15-84 months). Figure 1 shows the relapse-free survival curve of all 24 CRs. The pattern of relapses was characterized by: three local reccurrences (relapse in the vicinity of the removed tumor), and two relapses in other sites; all relapses were histologically confirmed as low-grade. In particular, one patient with breast MALT showed disease recurrence on the contralateral side and one with salivary gland MALT had disease relapse in bilateral multiple lymph nodes on both sides of the neck and supra-clavicular fossa, right axilla, and inguinal lymph nodes.
Two of these five relapsed patients obtained second CRs. In particular, an orbital soft tissue MALT submitted to local radiation therapy as first-line treatment, was given polychemotherapy (CVP) after local relapse; the patient with breast involvement who had a contralateral recurrence was retreated with radiation therapy. These two CR patients are still alive without disease at 12 and 25 months after their second treatment responses.
The remaining three patients are alive with disease, two (one with skin disease and one with salivary gland involvement) in PR after second-line treatment, while the third (local recurrence of a pulmonary lymphoma) is undergoing chemotherapy.
Discussion
The concept of lymphoma arising from mucosa-associated lymphoid tissue was proposed by Isaacson and Wright in 1983 to describe a distinctive type of extranodal low-grade B-cell lymphoma with unique morphological, immunophenotypic, and clinical features [1] . Their unusual histologic features make these lymphomas difficult to classify by standard classification schemes. The gastrointestinal tract (especially the stomach) is the most frequently involved extranodal location, representing 60%-70% of all MALT lymphomas. Numerous other extranodal sites involved by MALT lymphoma have been described; the nongastrointestinal organ most frequently involved by MALT lymphoma is the lung.
Paradoxically, MALT is absent from the normal stomach, and must be acquired before gastric lymphoma can develop. The main causative factor for the aquisition of gastric MALT is colonization of the stomach by H. pylori, and it has been shown that eradication of the organism can lead to regression of the lymphoma [21] [22] [23] . In the lung MALT is also acquired by infection (follicular bronchiectasis) and by autoimmune disease [27] , while in the salivary and thyroid glands it is acquired by autoimmune disease (Sjogren's disease and Hashimoto's thyroiditis) [28, 29] . It has also been hypothesised that orbital MALT lymphomas may be preceded by a reactive or inflammatory lesion before becoming neoplastic [30] .
In this study, we evaluated the clinico-pathologic presentation, clinical course and results of treatment in a series of patients with stage IE nongastrointestinal low-grade MALT lymphoma. Our results are in agreement with those described by Thieblemont [31] , that is, a predominance of female patients, median age of approximately 55-60 years, and involvement of the lung as one of the most frequent extranodal sites outside the gastrointestinal tract. Moreover, in our series all patients presented stage IE and, histologically, the tumours were all of the low-grade variety. It is also noteworthy that the absence of a pre-existing autoimmune disease was a particular feature of this series.
In the current study, 24 of 24 (100%) of the patients achieved CR. Despite the absence of maintenance therapy, only five (21%) relapses were observed among the 24 CRs, with a 79% relapse-free survival at a median follow-up of 32 months (range 12-78 months). Specific therapeutic approaches were used for the different organs, ranging from chemotherapy for lung disease to surgical excision and radiotherapy or local a-IFN for orbital, lung and conjunctival MALT lymphoma, respectively. Different chemotherapy regimens were employed due to changes in institutional protocols. To the best of our knowledge this is the first report to validate the activity of local a-IFN in MALT lymphoma of conjunctiva and lachrymal glands.
All of the different locations of MALT lymphoma exhibited the same favorable outcome. In correspondence with the localized form of the disease and its low histology grade, LDH and |32-microglobulin levels were always normal, as was found also by other investigators [32, 33] .
Our data confirm: 1) the effectiveness of local radiotherapy in the management of orbital MALT lymphoma; 2) the effectiveness of local administration of a-IFN in the treatment of conjunctival MALT lymphoma; 3) a role for the chemotherapeutic approach to MALT lymphomas of the lung. These specific results confirm that radiation therapy and chemotherapy may be considered equally effective in the treatment of these lymphomas in relation to the involved site.
Why the prognosis of MALT lymphoma is more favorable than that of other extranodal lymphomas remains unclear, but possibilities include the specificity of lymphocyte homing patterns, non-circulation of some marginal cells, and antigenic dependency of the lymphoma. On the other hand, if we compare these localized-stage MALT lymphomas with stage I nodal lymphomas, the outcome in terms of relapse-free survival should be better for the nodal ones. It is clinically significant that the prognosis of MALT lymphoma is more dependent on the stage (as verified byThieblemont et al.) [31] than on the histopathological grade.
In conclusion, correct histological diagnosis and staging are very important for the treatment and outcome of localized (stage IE) low-grade MALT lymphomas, since administration of chemotherapy, local radiotherapy, and local a-IFN produce good results and long-lasting survival with a low rate of side effects.
